Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial.
Trigo-Rodríguez M, Cárcel S, Navas A, Espíndola-Gómez R, Garrido-Gracia JC, Esteban Moreno MÁ, León-López R, Pérez-Crespo PMM, Alonso EA, Vinuesa D, Romero-Palacios A, Pérez-Camacho I, Gutiérrez-Gutiérrez B, Martínez-Marcos FJ, Fernández-Roldán C, León E, Caño AA, Corzo-Delgado JE, Perez-Nadales E, Riazzo C, de la Fuente C, Jurado A, Torre-Cisneros J, Merchante N. Trigo-Rodríguez M, et al. Open Forum Infect Dis. 2023 Mar 11;10(4):ofad133. doi: 10.1093/ofid/ofad133. eCollection 2023 Apr. Open Forum Infect Dis. 2023. PMID: 37035487 Free PMC article.
Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease.
Merchante N, Girón-González JA, González-Serrano M, Torre-Cisneros J, García-García JA, Arizcorreta A, Ruiz-Morales J, Cano-Lliteras P, Lozano F, Martínez-Sierra C, Macías J, Pineda JA; Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Merchante N, et al. AIDS. 2006 Jan 2;20(1):49-57. doi: 10.1097/01.aids.0000198087.47454.e1. AIDS. 2006. PMID: 16327319
[Darunavir in HIV/HVC/HVB coinfection].
Rivero A, Camacho A, Pérez-Camacho I, Torre-Cisneros J. Rivero A, et al. Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 10:37-42. doi: 10.1016/s0213-005x(08)76552-2. Enferm Infecc Microbiol Clin. 2008. PMID: 19195458 Review. Spanish.
[Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
Camacho A, Pérez-Camacho I, Rivero A, Natera C, García-Lázaro M, Castón JJ, Gallo M, Kindelán JM, Torre-Cisneros J. Camacho A, et al. Enferm Infecc Microbiol Clin. 2010 Apr;28(4):239-44. doi: 10.1016/j.eimc.2009.04.003. Epub 2009 Aug 3. Enferm Infecc Microbiol Clin. 2010. PMID: 19647900 Spanish.
[Cardiovascular risk factors associated with antiretroviral therapy].
Pérez-Camacho I, Camacho A, Torre-Cisneros J, Rivero A. Pérez-Camacho I, et al. Enferm Infecc Microbiol Clin. 2009 Sep;27 Suppl 1:24-32. doi: 10.1016/S0213-005X(09)73442-1. Enferm Infecc Microbiol Clin. 2009. PMID: 20172412 Review. Spanish.
Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin.
Macías J, del Valle J, Rivero A, Mira JA, Camacho A, Merchante N, Pérez-Camacho I, Neukam K, Rivero-Juárez A, Mata R, Torre-Cisneros J, Pineda JA; Grupo para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas. Macías J, et al. J Antimicrob Chemother. 2010 Oct;65(10):2204-11. doi: 10.1093/jac/dkq272. Epub 2010 Jul 22. J Antimicrob Chemother. 2010. PMID: 20656678
Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine.
Merchante N, Pérez-Camacho I, Mira JA, Rivero A, Macías J, Camacho A, Gómez-Mateos J, García-Lázaro M, Torre-Cisneros J, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas. Merchante N, et al. Antivir Ther. 2010;15(5):753-63. doi: 10.3851/IMP1612. Antivir Ther. 2010. PMID: 20710057
Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
Rivero-Juárez A, Mira JA, Pérez-Camacho I, Macías J, Camacho A, Neukam K, Torre-Cisneros J, Merchante N, Pineda JA, Rivero A; Viral Hepatitis Study Group, part of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI) (Andalusian Society for Infectious Diseases). Rivero-Juárez A, et al. J Antimicrob Chemother. 2011 Jun;66(6):1351-3. doi: 10.1093/jac/dkr091. Epub 2011 Mar 17. J Antimicrob Chemother. 2011. PMID: 21415037
Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
Rivero-Juárez A, Camacho Espejo A, Perez-Camacho I, Neukam K, Caruz A, Mira JA, Mesa P, García-Lázaro M, Torre-Cisneros J, Pineda JA, Rivero A. Rivero-Juárez A, et al. J Antimicrob Chemother. 2012 Jan;67(1):202-5. doi: 10.1093/jac/dkr439. Epub 2011 Oct 11. J Antimicrob Chemother. 2012. PMID: 21990051
373 results